Ingevity Q3 sales fall on Road Markings divestiture

By Reuters News


Overview

  • US specialty materials firm's Q3 sales fell 8% yr/yr, mainly due to Road Markings divestiture

  • Q3 net income and adjusted EPS rose from prior year

  • Company repurchased $39 mln in shares during Q3


Outlook

  • Ingevity narrows 2026 adjusted EBITDA outlook to $385 mln–$395 mln, maintaining midpoint

  • Company expects 2026 net sales of about $1.1 bln and diluted adjusted EPS of $5.25–$5.45

  • Free cash flow for 2026 seen at $220 mln–$230 mln, excluding litigation settlement payment


Result Drivers

  • ROAD MARKINGS DIVESTITURE - Co said sales fell 8% yr/yr primarily due to the April 2026 sale of the Road Markings product line

  • PERFORMANCE MATERIALS DEMAND - Resilient North American demand for Performance Materials, supported by hybrid vehicle trends and higher filtration sales, offset lower volumes in China and Europe

  • PAVEMENT TECHNOLOGIES PRESSURE - Softer demand and higher input and logistics costs weighed on Pavement Technologies segment results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$305.10 mln

$304.60 mln (2 Analysts)

Q3 EPS from Continuing Operations

$1.46

Q3 Adjusted EPS

$1.63

Q3 Net Income from Continuing Operations

$51.1 mln

Q3 Gross Profit

$132.80 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the diversified chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Ingevity Corporation is $92.00, about 24.9% above its November 3 closing price of $73.63

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago


Reuters Recommended Reads

  • Nov 2 - Celanese Q3 sales rise 6%

  • Nov 2 - Chemours Q3 adjusted profit misses estimates despite titanium pricing gains

  • Nov 4 - AdvanSix Q3 sales rise on higher pricing


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk